Intercept Pharmaceuticals (ICPT)

[osaffer]

ICPT is game over, dont deny that

Genfit is number one in the Nash, the publication in Gastroenterology demonstrates the efficiency of Genfit against Nash.

ICPT has NOT yet started the recruitment of patient for Phase 3, during Conference call, CEO was not able to give a date, and so, ICPT has received the green light for Phase 3 a long time before Genfit ... While for Genfit is totally different .

If I were you, I will buy Genfit while the price is still so low.

Most of Analyst decrease the conscensus of ICPT, when the US Analyst will enforce their projection on Genfit, the price will rise rapidly ...

Fundamentals are strong with Genfit, no doubt on that, publication is there, with all experts of Nash ...

Even Adam Feuerstein, big, defender of ICPT cannot attack Genfit anymore ...

Things are changing ... take the good train ...